C HEALTH GP (08225) Successfully Recovers RMB 11.0869 Million from Related Parties as of November 30

Stock News
2025/12/01

C HEALTH GP (08225) announced that, as disclosed in its 2024 Annual Report, the company's total accounts receivable stood at RMB 128 million as of December 31, 2024, with appropriate impairment provisions made in accordance with accounting standards. These receivables primarily arose from the group's ordinary business operations and are common in the industry.

Since the annual report disclosure, the company has actively pursued debt recovery, implementing tailored strategies based on debtor circumstances. Key progress includes:

1. **Recovery from Related Parties** The company strengthened collection efforts through dedicated mechanisms, ongoing communication, and formal notices. As of November 30, 2025, RMB 11.0869 million has been successfully recovered from related parties. For outstanding amounts, arbitration proceedings have been initiated and accepted, with legal follow-ups underway.

2. **Recovery from Non-Related Parties** - **Cooperative Clients**: Through improved engagement and negotiations, the company secured additional repayments totaling RMB 4.4514 million, with repayment plans progressing steadily. - **Challenging Cases**: For long-overdue or financially distressed clients, third-party agencies have been engaged for evaluation and disposal, alongside legal actions to safeguard interests. - **High-Risk Receivables**: The company has pursued all legal measures, including applying to list debtors as失信被执行人 (discredited persons subject to enforcement), while monitoring their assets for actionable opportunities.

3. **Internal Management Enhancements** To improve working capital quality, the company established a "Receivables Management Committee" led by the finance department, strengthening end-to-end controls from credit assessment to payment terms to mitigate new risks.

**Next Steps** The company will continue lawful efforts—such as negotiations, enforcing arbitration awards, and preparing litigation—to maximize recoveries. Progress will be reported to the board periodically, with disclosures made per exchange regulations.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10